Medicinal potential of ciprofloxacin and its derivatives

被引：63
作者：
Castro, William [1 ]
Navarro, Maribel [2 ]
Biot, Christophe [3 ]
机构：
[1] Inst Venezolano Invest Cient, Ctr Quim, Lab Quim Bioinorgan, Caracas 1020A, Venezuela
[2] Murdoch Univ, Sch Chem & Math Sci, Murdoch, WA 6150, Australia
[3] Univ Lille 1, Unite Glycobiol Struct & Fonct, UMR CNRS 8576, F-59650 Villeneuve Dascq, France
来源：
FUTURE MEDICINAL CHEMISTRY | 2013年 / 5卷 / 01期
关键词：
D O I：
10.4155/fmc.12.181
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Ciprofloxacin (CP) is a fluoroquinolone that is highly active against diverse microorganisms. At concentrations less than 1 mu g/ml it is active against a diverse types of bacteria, including Staphylococcus aureus, Staphylococcus epidermidis,Bacillius subtilius, Escherichia coli and Mycobacterium tuberculosis. In addition, it has shown to be effective against other diseases such as malaria, cancer and AIDS. The extended antimicrobial activity, lack of plasmid-mediated resistance, large volume of distribution and minimal adverse effects of CP are therapeutically advantageous. In the pursuit of increasing their effectiveness against these diseases and prevent unwanted resistance, researchers have begun to synthesize a class of organic, inorganic and organometallic derivatives, which have displayed interesting activities. This review describes the development and recent advances on the evaluation of CP and its derivatives as a new class of drugs with potential for clinical development.
引用
收藏
页码：81 / 96
页数：16
相关论文
共 118 条
[1]  
Hooper D.C., Rubinstein E., Quinolone Antimicrobial Agents, (2003)
[2]  
King D.E., Malone R., Lilley S.H., New classification and update on the quinolone antibiotics, Am. Fam. Phys., 61, 9, pp. 2741-2748, (2000)
[3]  
Lietman P.S., Fluoroquinolone toxicities: An update, Drugs., 49, pp. 159-163, (1995)
[4]  
Emami S., Shafiee A., Foroumadi A., Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria, Mini Rev. Med. Chem., 6, pp. 375-386, (2006)
[5]  
Hooper D.C., Fluoroquinolone resistance among Gram-positive cocci, Lancet Infect. Dis., 2, pp. 530-538, (2002)
[6]  
Turel I., The interactions of metal ions with quinolone antibacterial agents, Coord. Chem. Rev., 232, pp. 27-47, (2002)
[7]  
Scully B.E., Jules K., Chin N.X., Et al., Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin, Am. J. Med., 82, pp. 336-338, (1987)
[8]  
Abraham D.J., Burger's Medicinal Chemistry Drug Discovery, pp. 582-587, (2003)
[9]  
Campoli-Richards D.M., Monk J.P., Price A., Et al., Ciprofloxacin a review of its antibacterial activity pharmacokinetics properties and therapeutics use, Drugs, 35, pp. 373-447, (1998)
[10]  
Eliopoulos G.M., In vitro activity of fluoroquinolones against Gram-positive bacteria, Drugs, 49, pp. 48-57, (1995)
12345678910